SynthesisBiomarkers in medicine2024
Update prognostic potency of surfactant protein D (SP-D) in the COVID-19 landscape: an In-depth meta-analytical exploration.
Synthesis in Biomarkers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- VEGF-A in COVID-19: a systematic review and meta-analytical approach to its prognostic value.Clinical and experimental medicine · 2025Pooled it
- The Impact of Surfactant Protein-D Gene Polymorphism on COVID-19 Clinical Outcomes.Immunity, inflammation and disease · 2026Article
- Drug Monitoring of Therapy with Midazolam in Patients with ARDS: A Single-Center Prospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".Biomarker insights · 2026Review
- Investigation of ESR Values in the Diagnosis of Malignancies: A Cross-Sectional Study.Health science reports · 2025Article
- Evaluation of Complete Blood Count Parameters in Patients With Diabetes Mellitus: A Systematic Review.Health science reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSurfactant Protein D (SP-D), a key component of the innate immune system, has attracted significant interest for its potential role in the pathophysiology and prognosis of COVID-19. This systematic review and meta-analysis aim to clarify the prognostic importance of SP-D levels in COVID-19 patients.
methodsA comprehensive literature search was conducted using PubMed, Web of Science, Cochrane Library, Scopus, EMBASE, and Google Scholar, covering studies published from January 2000 to January 2024. The inclusion criteria focused on studies measuring SP-D levels in the serum or plasma of COVID-19 patients, comparing severe and non-severe cases. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model to assess overall effect sizes. Meta-regressions and subgroup analyses were performed to identify potential sources of heterogeneity, including patient age, assay techniques, and gender ratio.
resultsThe meta-analysis incorporated data from nine studies involving 5,410 COVID-19 patients. Elevated SP-D levels were significantly correlated with increased disease severity, yielding an SMD of 0.642 (95% CI: 0.314 to 0.870;
conclusionThis meta-analysis confirms the prognostic significance of SP-D in the context of COVID-19. Elevated SP-D levels are associated with severe disease outcomes, highlighting its potential as a prognostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.